Exploring the idiotypes of insulin antibodies as markers for remission in Type 1 diabetes

Diabetic Medicine

Volumn 21, Issue 12, 2004, Pages 1316-1324

  Devendra, D ^a,c   Galloway, T S ^b   Norton, S J ^a   Wilkin, T J ^a  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

^c UNIVERSITY OF COLORADO DENVER   (United States)

Author keywords

Honeymoon period; Insulin antibody; Insulin autoantibody; Metabolic remission; Phage display; Type 1 diabetes

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; IDIOTYPIC ANTIBODY; INSULIN ANTIBODY;

AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ARTICLE; AUTOIMMUNE DISEASE; CELL DESTRUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INSULIN BINDING; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; PANCREAS ISLET BETA CELL; PHAGE DISPLAY; REMISSION;

ADOLESCENT; ANTIBODY SPECIFICITY; AUTOANTIBODIES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOGLOBULIN IDIOTYPES; INSULIN; MALE; MIDDLE AGED; PEPTIDE LIBRARY; RADIOLIGAND ASSAY; REMISSION INDUCTION;

EID: 10244249174     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01344.x     Document Type: Article

References (29)

1. Atkinson MA, Eisenbarth GS. Type 1 diabetes. New perspectives on disease pathogenesis and treatment. Lancet 2001; 358: 221-229.
2. Martin S, Wolf-Eichbaum D, Duinkerken G, Scherbaum WA, Kolb H, Noordzij JG et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001; 345: 1036-1040.
3. Castano L, Eisenbarth GS. Type I diabetes: a chronic autoimmune disease of man, mouse, and rat. Ann Rev Immunol 1990; 8: 647-679.
4. Devendra D, Eisenbarth GS. Immunologic endocrine disorders. J Allergy Clin Immunol 2003; 111 (Suppl 2): 624-636.
5. Wilkin T, Hoskins PJ, Armitage M, Rodier M, Casey C, Diaz JL et al. Value of insulin autoantibodies as serum markers for insulin-dependent diabetes mellitus. Lancet 1985; 1: 480-481.
6. Bingley PJ, Bonifacio E, Ziegler AG, Schatz DA, Atkinson MA, Eisenbarth GS. Position statement on prediction of type 1 diabetes. Diabetes Care 2000; 24: 398.
7. Verge CF, Stenger D, Bonifacio E, Colman PG, Pilcher C, Bingley PJ et al. Combined use of autoantibodies (IA-2ab, Gadab, IAA, ICA) in type 1 diabetes: combinatorial islet autoantibody workshop. Diabetes 1998; 47: 1857-1866.
8. Krischer JP, Cuthbertson DD, Yu L, Orban T, Maclaren N, Jackson R et al. Screening strategies for the identification of multiple antibody-positive relatives of individuals with type 1 diabetes. J Clin Endocrinol Metab 2003; 88: 103-108.
9. Marks JB, Skyler JS. Immunotherapy of type I diabetes mellitus. J Clin Endocrinol Metab 1991; 72: 3.
10. Dupre J, Jenner MR, Mahon JL, Purdon C, Rodger NW, Stiller CR. Endocrine-metabolic function in remission-phase IDDM during administration of cyclosporine. Diabetes 1991; 40: 598-604.
11. Vague P, Vialettes B, Lassmann-Vague V, Vallo JJ. Nicotinamide may extend remission phase in insulin-dependent diabetes. Lancet 1987; 1: 619-620.
12. Mayer A, Rharbaoui F, Thivolet C, Orgiazzi J, Madec AM. The relationship between peripheral T cell reactivity to insulin, clinical remissions and cytokine production in type 1 (insulin-dependent) diabetes mellitus. J Clin Endocrinol Metab 1999; 84: 2419-2424.
13. Martin S, Pawlowski B, Greulich B, Ziegler AG, Mandrup-Poulsen T, Mahon J. Natural course of remission in IDDM during 1st year after diagnosis. Diabetes Care 1992; 15: 66-74.
14. Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science 1990; 249: 386-390.
15. Devendra D, Galloway TS, Horton SJ, Evenden A, Keller U, Wilkin TJ. The use of phage display to distinguish insulin autoantibody (IAA) from insulin antibody (IA) idiotypes. Diabetologia 2003; 46: 802-809.
16. Williams AJ, Bingley PJ, Bonifacio E, Palmer JP, Gale EA. A novel micro-assay for insulin autoantibodies. J Autoimmun 1997; 10: 473-478.
17. Yu L, Rewers M, Gianani R, Kawasaki E, Zhang Y, Verge C et al. Anti-islet autoantibodies develop sequentially rather than simultaneously. J Clin Endocrinol Metab 1996; 81: 4264-4267.
18. Rowley MJ, Scealy M, Whisstock JC, Jois JA, Wijeyewickrema LC, Mackay IR. Prediction of the immunodominant epitope of the pyruvate dehydrogenase complex E2 in primary biliary cirrhosis using phage display. J Immunol 2000; 164: 3413-3419.
19. Schatz DA, Bingley PJ. Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT). J Pediatr Endocrinol Metab 2001; 14 (Suppl 1): 619-622.
20. Pinkney JH, Bingley PJ, Sawtell PA, Dunger DB, Gale EAM. Presentation and progress of childhood diabetes mellitus: a prospective population-based study. The Bart's-Oxford Study Group. Diabetologia 1994; 37: 70-74.
21. Knip M, Sakkinen A, Huttunen NP, Kaar ML, Lankela S, Mustonen A et al. Postinitial remission in diabetic children-an analysis of 178 cases. Acta Paediatr Scand 1982; 71: 901-908.
22. Agner T, Damm P, Binder C. Remission in IDDM: prospective study of basal C-peptide and insulin dose in 268 consecutive patients. Diabetes Care 1987; 10: 164-169.
23. Schiffrin A, Suissa S, Poussier P, Guttmann R, Weitzner G. Prospective study of predictors of beta-cell survival in type I diabetes. Diabetes 1988; 37: 920-925.
24. Wallensteen M, Dahlquist G, Persson B, Landin-Olsson M, Lernmark A, Sundkvist G et al. Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia 1988; 31: 664-669.
25. Ortqvist E, Falorni A, Scheynius A, Persson B, Lernmark A. Age governs gender-dependent islet cell autoreactivity and predicts the clinical course in childhood IDDM. Acta Paediatr 1997; 86: 1166-1171.
26. Sabbah E, Savola K, Kulmala P, Veijola R, Vahasalo P, Karjalainen J et al. Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes. The Childhood Diabetes In Finland Study Group. J Clin Endocrinol Metab 1999; 84: 1534-1539.
27. Schiffrin A, Suissa S, Weitzner G, Poussier P, Lalla D. Factors predicting course of B-cell function in IDDM. Diabetes Care 1992; 15: 997-1001.
28. Kolb H, Dannehl K, Gruenklee D, Zielasek J, Bertrams J, Hubinger A et al. Prospective analysis of islet cell antibodies in children with type I (insulin-dependent) diabetes. Diabetologia 1988; 31: 189-194.
29. Felici F, Galfre G, Luzzago A, Monaci P, Nicosia A, Cortese R. Phage-displayed peptides as tools for characterization of human sera. Methods Enzymol 1996; 267: 116-129.